CD274 and small cell lung carcinoma: Preclinical study and the phase II MATCH trial (NCT04622228) evaluated LDRT combined with PD-L1 inhibitors in ES- SCLC, well tolerated and produced durable responses: the confirmed overall response rate was 87.5% (95% CI 75.9–94.8%), median PFS 6.9 months (95% CI 5.4–9.3), and median OS 16.9 months (95% CI 14.0–32.9) (100).